The short answer. Oxytocin is FDA-approved, as Pitocin and several generic injections. Because it is a component of an approved drug, a 503A pharmacy may compound it for a named patient, and as of September 26, 2026 outsourcing facilities may use it under FDA’s 503B Category 1 policy. The copy rules and the approved label set the limits.
| FDA approved | Yes. Pitocin (NDA 018261) and other oxytocin injections, for use in labor and postpartum care. |
|---|---|
| Regulatory class | A drug under an NDA. At nine amino acids it is not a protein, and it did not move to the biologics framework in 2020. |
| 503A pharmacy | Eligible as a component of an approved drug. Compounded injections are restricted by the essentially-a-copy rules. |
| 503B outsourcing facility | Category 1, marked by FDA as a component of an approved drug, under FDA’s 503B interim policy. |
| Latest FDA action | Warning letters to outsourcing facilities QuVa Pharma and Central Admixture Pharmacy Services, 2024. |
| MDside position | Patient-specific from a 503A pharmacy, with the prescriber’s reasoning documented. Never research-labeled product. |
| Last verified | 2026-09-26 |
Why oxytocin sits outside the bulks categories
The 503A bulks list and its categories exist for substances with no USP monograph that are not part of an approved drug. Oxytocin is part of several approved drugs, so it needs no nomination and appears in no 503A category. That is the same route that makes sermorelin and bremelanotide compoundable.
The copy rules apply to injections
Approved oxytocin injections are on the market. A compounded injection at the same or a similar strength is presumptively essentially a copy, and the same three tests apply as for semaglutide: the copy definition, a documented significant difference for the identified patient, and FDA’s policy of not acting at four or fewer copy prescriptions a month. Nasal, sublingual and troche forms use routes that no marketed product currently covers. Whether that takes a given preparation outside the copy definition is a question for the pharmacy to answer in writing.
The label is narrow, and it is a hospital label
Pitocin’s approved uses are in labor and after delivery. Its label says that for induction it should be given only by IV and with adequate medical supervision in a hospital, and that it is not indicated for elective induction. Uses sold in wellness settings, such as mood, bonding, sexual function or weight, are off-label. The prescriber owns that decision, and marketing it as an approved use is a misbranding problem.
Where oxytocin goes wrong
The failures in FDA’s record are quality failures. FDA’s 2024 warning letters cited QuVa Pharma over an oxytocin IV bag recalled for an incorrect formulation, and Central Admixture Pharmacy Services over unreliable oxytocin stability data. A lawful ingredient made badly is still the clinic’s problem when it reaches a patient.
What this means for you
If oxytocin is on your menu, source it from a licensed 503A pharmacy for named patients, get the pharmacy’s position on the copy rules for the route you use, and keep the prescriber’s reasoning in the chart. Remove marketing that presents an off-label use as approved. Our hormone therapy program is sourced this way.
Read next
Frequently asked questions
Can oxytocin be compounded?
Yes. Oxytocin is a component of FDA-approved drugs, so a 503A pharmacy may compound it for a named patient without a nomination. As of September 26, 2026 outsourcing facilities may use it under FDA’s 503B Category 1 policy. Compounded injections similar to a marketed product face the essentially-a-copy limits.
Is compounded oxytocin nasal spray legal?
It can be, from a 503A pharmacy for a named patient, because oxytocin is an approved-drug component. No nasal product is currently marketed, since the Syntocinon nasal solution is discontinued. The pharmacy should document its position on the copy rules, and any use outside the approved label is off-label.
Is oxytocin approved for weight loss or mood?
No. Pitocin and the other approved oxytocin injections are approved for use in labor and after delivery. Uses such as weight, mood, bonding or sexual function are off-label. The prescriber owns that clinical decision, and it cannot be advertised as an approved use.
Primary sources. Last verified September 26, 2026. Corrections are welcome: contact us.
- Drugs@FDA, Pitocin (oxytocin injection), NDA 018261
- Pitocin prescribing information (2021)
- FDA, list of approved NDAs for biological products deemed to be BLAs on March 23, 2020
- FDA guidance, Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (Jan 2018)
- FDA guidance, Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B
- FDA, 503A bulk drug substance categories (updated May 14, 2026)
- FDA, 503B bulk drug substance categories (updated Mar 21, 2025)
- FDA, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (Jan 2025)
- FDA, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B (Jan 2025)
- FDA warning letter, QuVa Pharma (Jan 26, 2024)
- FDA warning letter, Central Admixture Pharmacy Services (Mar 25, 2024)
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.